Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

Also called NCT01322347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 294 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01322347
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01322347. Randomized; single masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
Condition
Renal Failure Chronic Requiring Hemodialysis
Intervention (Drug)
Soluble Ferric Pyrophosphate (SFP)
Intervention (Device)
Standard dialysate
Lead sponsor
Rockwell Medical Technologies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01322347
Content hash
fb9c6b37d19dac6ad93aa23ad6dfedd30127e0b443451cafc7e3590946d2f9ae